S2 Table. Resource use for monitoring based on EASL Clinical Practice and Treatment Guidelines

Item		Details							Resource use*				
Initial evaluation of a new pat	ient w	ith conf	ïrmed	HCV b	efore s	tarting	treatm	ent (fe	or all tre	eatmer	ıts)		
Gastroenterology		Consultant-led outpatient visit, HCV screen (RNA),									1		
		SVR test, HIV RNA, Anti-HIV, liver function test,											
		alfa-fetoprotein(cirrhotic patients), alfa-antitrypsin,											
	1	thyrotropin, free T4, caeruloplasmin, iron											
Tests and investigations	1	Urea and electrolytes, glucose, full blood count,											
		ferritin, blood clotting factors, autoantibodies,									1		
		immunoglobulins, ultrasound scan of liver, HCV								-			
		genotype, endoscopy, HBV testing											
		MRI liver (cirrhotic patients)								0.15			
		Pulmonary function test (5% of patients)								0.05			
Further investigations before							oup (SC	OF, Po	egIFN+.	1	BOC, T	EL)	
Gastroenterology		Consultant-led outpatient vist								1			
Inpatient care		Day case (half an hour)								0.5			
Tests and investigations		Pregnancy test (5% of patients)								0.05			
		Full blood count, blood clotting factors, blood group,								1			
		HCV quantitative PCR								0.2			
		Ultrasound guided biopsy, liver biopsy (in pathology) Fibroscan/Fibrotest								0.2			
Manitania India and in Ind		Fibroscan/Fibrotest n of sofosbuvir treatment (number of visits or tests durin;											
monitoring auring certain aur treatment)	ation	of sofos	buvir i	treatme	nt (nui	nber oj	visits o	or tesi	ts aurin _g	g week	cs of		
Details 4 wks			8 wks 12 wks 16					16 wks	s 24 wks				
Consultant-led outpatient visit				4 5 (+1)									
HCV screen (RNA), SVR test		2	2			2 (+1)		6 (+1) 2 (+1)		2 (+1)			
Liver function test	3		4			5 (+1)		6 (+1)		6 (+1)			
Alfa-fetoprotein (cirrhotic only)		-		_		-	1		1		1		
Urea and electrolytes		3		4		-	5 (+1)		6 (+1)		6 (+1)		
Full blood count		3		4			5 (+1)		6 (+1)		6 (+1)		
Thyroid function test		-		-			1		1		1		
Blood clotting factors		2		2			2 (+1)		2 (+1)		2 (+1)		
		ttion of comparator treatment (number of visits or tests							, ,				
treatment)	anı all	on oj c	отра	iaioi l	cam	on (nu	mver O	, visii	s or test	5 unit	ng weer	w Oj	
Details	4 w	4 wks 8 v		vks 12 wk		ks ·	as 16 wks		24 w	24 wks		48 wks	
	C	NC	C	NC	C	NC	C	NC	C	NC	C	NC	
Consultant-led outpatient													
visit	4	4	6	6	8	7	9	8	12	10	22	16	
HCV screen (RNA), SVR	1	1	1	1	1	1	1	1	2	2	2	2	
test	1	1	1	1	1	1	1	1	2	2	2	2	
Liver function test	4	4	6	6	8	7	9	8	12	10	22	16	
Alfa-fetoprotein	-	-	-	-	1	-	1	-	2	1	2	1	
Urea and electrolytes	4	4	6	6	8	7	9	8	12	10	22	16	
Thyroid function test	-	-	-	-	1	1	1	1	2	2	4	4	
Full blood count	4	4	6	6	8	7	9	8	12	10	22	16	
Blood clotting factors	2	2	2	2	2	2	2	2	3	3	5	5	
Ultrasound scan of liver	-	-	-	-	-	-	-	-	-	-	1	-	
Endoscopy	-	-	-	-	-	-	-	-	-	-	1	-	

BOC, boceprevir; C, cirrhotic; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; MRI, magnetic resonance imaging; NC, non-cirrhotic; PegIFN, pegylated interferon; RBV, ribavirin; RNA, ribonucleic acid; SOF, sofosbuvir; SVR, sustained virological response; TEL, telaprevir

*resource use was checked by Swiss clinical experts; 1 stands for 100% of the patients